Enantioselective Michael Addition of Nitromethane to α,β -Enones Catalyzed by Chiral Quaternary Ammonium Salts. A Simple Synthesis of (*R*)-Baclofen

ORGANIC LETTERS 2000 Vol. 2, No. 26 4257-4259

E. J. Corey* and Fu-Yao Zhang

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138

corey@chemistry.harvard.edu

Received November 7, 2000

ABSTRACT



Enantioselective Michael addition of nitromethane to an $\alpha_{i}\beta$ -enone is a key step in the synthesis of (*R*)-baclofen.

Advances in understanding the three-dimensional pathways and transition states for the cinchona alkaloid catalyzed asymmetric dihydroxylation of olefins by osmium tetroxide¹ led to the development of rigid, structurally defined, chiral quaternary ammonium salts of type **1** for a variety of catalytic phase transfer reactions. With catalysts of type **1**, enantio-



selectivities of >20:1 were obtained in numerous alkylation,^{2–4} aldol,⁵ epoxidation,⁶ and Michael^{7,8} reactions. These chiral

catalysts can also be used to control diastereoselectivity, as demonstrated by highly effective and practical syntheses of HIV protease inhibitors by nitro aldol reactions of aldehydes with nitromethane.⁹ This Letter describes another new and useful reaction of nitromethane, the enantioselective Michael addition to α,β -enones to form chiral γ -nitro ketones. These versatile intermediates can serve as starting materials for a variety of further elaborated structures. Demonstrated herein is a route for the synthesis of the therapeutically useful GABA_B receptor agonist (*R*)-baclofen hydrochloride (**3**),¹⁰ a chiral γ -amino acid, via the corresponding γ -lactam. Racemic baclofen is used therapeutically to treat spasms caused by spinal cord injury or disease; however, the (*S*)-

(10) (a) Bowery, N. E. *Trends Pharm. Sci.* **1982**, *31*, 400. (b) Olpe, H. R.; Demiéville, H.; Baltzer, V.; Bencze, E. L.; Koella, W. P.; Wolf, P.; Haas, H. L. *Eur. J. Pharmacol.* **1978**, *52*, 133.

 ^{(1) (}a) Corey, E. J.; Noe, M. C. J. Am. Chem. Soc. **1996**, 118, 11038.
 (b) Corey, E. J.; Noe, M. C.; Ting, A. Tetrahedron Lett. **1996**, 37, 1735.

 ⁽²⁾ Corey, E. J.; Xu, F.; Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414.
 (3) Corey, E. J.; Bo, Y.; Busch-Petersen, J. J. Am. Chem. Soc. 1998, 120, 13000.

⁽⁴⁾ Corey, E. J.; Noe, M. C.; Xu, F. Tetrahedron Lett. 1998, 39, 5347.

⁽⁵⁾ Horikawa, M.; Busch-Petersen, J.; Corey, E. J. *Tetrahedron Lett.* **1999**, *40*, 3843.

⁽⁶⁾ Corey, E. J.; Zhang, F.-Y. Org. Lett. **1999**, *1*, 1287.

⁽⁷⁾ Zhang, F.-Y.; Corey, E. J. Org. Lett. 2000, 2, 1097.

⁽⁸⁾ For earlier work on the enantioselective alkylation of the benzophenone Schiff base of *tert*-butyl glycinate, see: (a) O'Donnell, M. J.; Bennett, W. D.; Wu, S. J. Am. Chem. Soc. **1989**, *111*, 2353. (b) O'Donnell, M. J.; Wu, S.; Huffman, J. C. Tetrahedron **1994**, *50*, 4507. (c) Lipkowitz, K. B.; Cavanaugh, M. W.; Baker, B.; O'Donnell, M. J. J. Org. Chem. **1991**, *56*, 5181.

⁽⁹⁾ Corey, E. J.; Zhang, F.-Y. Angew. Chem., Intl. Ed. 1999, 38, 1931.



enantiomer is essentially inactive. As a consequence there have been many studies on the synthesis of (*R*)-baclofen, including syntheses from (*S*)-glutamic acid¹¹ and (*S*)-*trans*-4-hydroxyproline,¹² syntheses involving resolution,^{13,14} and syntheses involving enzymatic reactions.^{15–17}

The pathway of the present catalytic enantioselective synthesis of (*R*)-baclofen is outlined in Scheme 1. Reaction of 10 equiv of nitromethane with 4-chlorobenzylidine-acetophenone, the cinchoninium salt **5** (10 mol %), and powdered cesium fluoride (10 equiv) in toluene at -40 °C with stirring for 36 h produced the crystalline Michael adduct

(11) Herdeis, C.; Hubmann, H. P. Tetrahedron: Asymmetry 1992, 3, 1213.

(12) Yoshifuji, S.; Kaname, M. Chem. Pharm. Bull. 1995, 43, 1302.

(13) Langlois, N.; Dahuron, N.; Wang, H.-S. Tetrahedron 1996, 52, 15117.

(14) Allan, R. D.; Bates, M. C.; Drew, C. A.; Duke, R. K.; Hambley, T.
 W.; Johnston, G. A. R.; Mewett, K. N.; Spence, I. *Tetrahedron* 1990, 46, 2511.

(15) Mazzini, C.; Lebreton, J.; Alphand, V.; Furstoss, R. Tetrahedron Lett. 1997, 38, 1195.

(16) Chênevert, R.; Desjardins, M. *Tetrahedron Lett.* 1991, *32*, 4249.
(17) Brenna, E.; Caraccia, N.; Fuganti, C.; Fuganti, D.; Grasselli, P. *Tetrahedron: Asymmetry* 1997, *8*, 3801.

(18) The Michael reaction of nitromethane with benzalacetophenone is similar to the examples described above, the (S) adduct predominating with the cinchonidium catalyst 2 and the R adduct predominating with the diastereometric cinchoninium catalyst 5.

(19) A mixture of powdered, flame-dried CsF (1.52 g, 10.0 mmol), the chiral cinchoninium salt 5 (66 mg, 0.1 mmol), and chlorochalcone 4 (243 mg, 1.0 mmol) in toluene (2.5 mL) was cooled to -40 °C and treated with nitromethane (0.54 mL, 10 mmol). The mixture was stirred at -40 °C for 36 h and then diluted with 10 mL of Et_2O and 10 mL of water. The organic phase was separated, concentrated, and purified by flash chromatography (silica gel, 3:1 hexanes:ethyl acetate) to afford (R)-6 (270 mg, 89% yield, 70% ee) as a colorless solid: mp 110–112 °C; $[\alpha]^{23}_{D} = +17.9$ (c = 1, CH₂Cl₂); FTIR (film) 1682.9 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 7.91– 7.21 (m, 9H), 4.83 (dd, J = 12.4 and 6.4 Hz, 1H), 4.65 (dd, J = 12.4 and 8.0 Hz, 1H), 4.21 (m, 1H), 3.45 (dd, J = 17.6 and 6.8 Hz, 1H), 3.39 (dd, J = 17.6 and 7.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 196.3, 137.6, 136.2, 133.7, 129.2, 129.0, 128.9, 128.8, 128.0, 79.5, 41.5, 38.9 ppm; HRMS (CI^+) calcd $[C_{16}H_{14}CINO_3 + NH_4]^+$ 321.1006, found 321.1002. Enantio-selectivity was determined by HPLC analysis with a Chiralcel AD column, 10% isopropyl alcohol in hexanes, 1.0 mL/min, $\lambda = 254$ nm, retention times minor 18.1 min, major 25.9 min. One recrystallization from ethyl acetatehexane gave colorless crystals: mp 121–122 °C; $[\alpha]^{23}_{D}$ +24.3 (c = 1, CH₂Cl₂); ee 95%.

6 with *R/S* selectivity of 85/15 in 89% yield. Recrystallization of this product from EtOAc-hexane furnished **6** of 95% ee with good recovery. Baeyer–Villiger oxidation of this material afforded the γ -nitro ester **7** as a colorless solid, mp 99–100 °C, $[\alpha]^{23}_{\text{D}}$ –19 (c = 1, CH₂Cl₂), in 90% yield. Reduction of **7** in methanol with 10 equiv of sodium borohydride in the presence of nickel boride (prepared in situ from 1 equiv of NiCl₂ and 5 equiv of NaBH₄) at 23 °C for 30 min gave the (*R*)- γ -lactam **8**, mp 116–117 °C, $[\alpha]^{23}_{\text{D}}$ –37 (c = 1, CH₃OH) (65%), the spectral and physical data for which matched those previously reported.¹³ Hydrolysis of γ -lactam **8** in 5 N aqueous HCl at reflux for 4 h afforded (*R*)-baclofen hydrochloride (**3**), $[\alpha]^{23}_{\text{D}}$ –1.5 (c = 1, H₂O), mp 200 °C (dec).

The enantiomer of **3** has also been synthesized enantioselectively by the approach outlined in Scheme 1 using as the initial step the Michael reaction of nitromethane to the α,β -enone **4** with the cinchonidium salt **2** as catalyst and CsF as base in toluene at -40 °C for 36 h to afford the





(S)-enantiomer of **6** of 95% ee after a single recrystallization from EtOAc—hexane.¹⁸

The simplicity of the enantioselective methodology described herein is illustrated by the conversion of 4 to 6 using catalyst 5.¹⁹

The absolute stereochemical course of the enantioselective Michael addition of nitromethane to **4** catalyzed by the chiral quaternary ammonium salts **2** and **5** can be explained by the same type of pre-transition state assembly as previously discussed for other Michael reactions involving ClO⁻ or enolates as nucleophiles.^{6,7} Figure 1 shows two views (related by a 180° rotation about a vertical axis) of the transition state assembly for the addition of the contact ion pair of $CH_2NO_2^-$ and **2** to **4** forming *ent*-**6**.

OL0068344